Controlled clinical study on compound Decumbent Corydalis Rhizome and diclofenac in treatment of knee osteoarthritis.
- Author:
Chuan ZUO
;
Geng YIN
;
Xiao-Min CEN
;
Qi-Bing XIE
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
Corydalis;
chemistry;
Diclofenac;
administration & dosage;
Drugs, Chinese Herbal;
administration & dosage;
Female;
Humans;
Male;
Middle Aged;
Osteoarthritis, Knee;
drug therapy;
Rhizome;
chemistry;
Treatment Outcome
- From:
China Journal of Chinese Materia Medica
2015;40(1):149-153
- CountryChina
- Language:Chinese
-
Abstract:
To evaluate the efficacy and safety of compound Decumbent Corydalis Rhizome (DCR) in treating patients with knee osteoarthritis (OA). Totally 79 patients with knee osteoarthritis were selected from out-patient and inpatient departments of West China Hospital and randomly divided into the test group and the control group. The test group (n = 41) was given Compound DCR with the dosage of 1.8 g · d(-1), while the control group (n = 38) was administered with diclofenac sodium with the dosage of 75 mg · d(-1). After 12 weeks of treatment, the total efficacy rates based on patients/physicians evaluation for experimental and control groups were 68.29%, 63.41% and 71.05%, 63.16%, respectively, without significant difference between the two groups. Both of the two groups showed significant improvements in the main efficacy indexes (pain on walking 20 m) and minor indexes (tenderness on palpation, Western Ontario and McMaster Universities OA index (WOMAC) and Short-Form Health Survey (SF-36 ), but without significant difference in efficacy between them. The incidence of related adverse events was 24.39% in the test group and 47.37% in the control group, respectively, with significant differences between the two groups (P < 0.05). In the controlled study, compound DCR is as efficient as diclofenac sodium but more tolerable, with a good clinical application prospect.
